A review of the response to oral antidiabetes agents in patients with type 2 diabetes. - Wikidata - wikimedia - TriplyDB

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

http://www.wikidata.org/entity/Q37750257

about

Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.

P2860

Q35564083-444EBAF9-CDDD-460F-A976-591761FD8EEC Q36073438-CD5A72A4-ECBC-4E28-9D55-0AE7AD876DCB Q44321908-A8DFD6C6-9D50-4124-847A-3C83C0C70978

P2860

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

http://www.wikidata.org/entity/Q37750257

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

@en

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

@nl

type

label

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

@en

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

@nl

prefLabel

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

@en

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

@nl

P1433

Q37750257-0F750900-8652-41C5-9629-1765D9FC2733

P1476

Q37750257-3A56FD72-87C1-44C4-A1C3-EEB72E48BF66

P2093

Q37750257-66785B56-31AC-48CF-9A8D-CC57C2EBBA28

Q37750257-D49369CC-1F72-4267-838C-0CF42590F3EC

P2860

Q37750257-01707938-4F7C-4FDF-87D0-017FFF2FB6FA

Q37750257-0236539B-1CBF-4A76-8BC0-CED85EB413F3

Q37750257-0335FC8C-8891-4B3C-A46B-2CF76E999A95

Q37750257-07C5B4C9-E35E-44D6-B0ED-D486E23A97F9

Q37750257-0DDCC93D-87EB-47C4-A513-F2EBCE247C0F

Q37750257-12441FC6-65D9-4BF0-A0F7-AE8E10FF5E44

Q37750257-1972E962-F7AC-4E1F-89AB-EB42933F82AB

Q37750257-1A281FD3-00ED-4008-AD96-A70CC7DED65A

Q37750257-254D7829-B1D2-4D42-AD34-933A238C2157

Q37750257-3E03D055-C464-4270-A7DD-3EF34A19E34F

P304

Q37750257-6ED898CB-9163-47CF-A1E0-1B0DA828BA02

P31

Q37750257-EBCBF4AF-74AD-490C-B14C-11443E1F2997

P356

Q37750257-EEE8F6BF-4302-42BF-80E4-57C694AAAF48

P407

Q37750257-FFDAB65B-5548-4BF8-8753-E3053187C5E5

P433

Q37750257-5756BB67-4E85-419C-B084-974D4BD04925

P478

Q37750257-90ED387D-1083-41F6-9B8B-791FFCE81014

P577

Q37750257-A938D667-685E-4D72-A548-0A988593D5C1

P698

Q37750257-48705A0C-C3FB-428E-8F6A-1F1990969BDC

P921

Q37750257-29766786-9E00-419B-94D3-39F78B85013E

P356

PGM.2010.05.2141

P1433

Postgraduate Medicine

P1476

A review of the response to oral antidiabetes agents in patients with type 2 diabetes.

@en

P2093

James R Gavin

http://www.w3.org/2001/XMLSchema#string

Nancy J Bohannon

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

Hypoglycemia in diabetes.

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

P304

43-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/PGM.2010.05.2141

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20463413

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes